PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. Along with an Orphan Drug Designation from the US FDA for all T-cell lymphomas, PTX-100 has secured approval of their Investigational New Drug (IND) application from the FDA – allowing them to proceed with a Phase 2 clinical trial which will focus on relapsed and refractory cutaneous T-cell lymphomas (r/r CTCL).

CellPryme is a high-performance cell therapy enhancement platform that can improve CAR-T efficacy. The CellPryme platform consists of two distinct components which can be used separately but have significant synergies when used together. CellPryme-M can be briefly added to standard manufacturing processes. CellPryme-A is used as an adjuvant alongside cellular immunotherapy.

The OmniCAR platform seeks to overcome the challenges of conventional CAR-T therapy including manufacturing, safety and reliability. OmniCAR is a modular, universal CAR platform based on technology licensed from UPenn and Oxford University. It allows unprecedented control and flexibility over current generation CAR-T approaches.